<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Albireo Pharma, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Albireo Pharma, Inc.

    Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Ron Cooper
    • FOUNDED
      2003
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Angle PLC

    Angle PLC

    ANGLE is a world leading liquid biopsy company with pioneering products in cancer ...

    ANGLE is a world leading liquid biopsy company ...

    Amount Raised:    $250,000
    Fundraising Status:    VT
    Filing Type:    PU
    Masimo Corporation

    Masimo Corporation

    We are a global medical technology company that develops, manufactures, and market...

    We are a global medical technology company that...

    Filing Type:    PU
    ZYPPAH, Inc.

    ZYPPAH, Inc.

    Stop the root cause of snoring by going directly after the tongue. ZYPPAH is the o...

    Stop the root cause of snoring by going directl...

    Amount Raised:    $359,340.00
    Fundraising Status:    EC
    Filing Type:    CF
    Assertio Therapeutics, Inc.

    Assertio Therapeutics, Inc.

    Assertio Therapeutics is committed to providing responsible solutions to advance p...

    Assertio Therapeutics is committed to providing...

    Filing Type:    PU
    Fibrocell Science Inc.

    Fibrocell Science Inc.

    Fibrocell is a cell and gene therapy company focused on improving the lives of peo...

    Fibrocell is a cell and gene therapy company fo...

    Filing Type:    PU
    Chimerix, Inc.

    Chimerix, Inc.

    Chimerix is a development-stage biopharmaceutical company dedicated to acceleratin...

    Chimerix is a development-stage biopharmaceutic...

    Filing Type:    PU
    Madrigal Pharmaceuticals, Inc.

    Madrigal Pharmaceuticals, Inc.

    Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing no...

    Madrigal Pharmaceuticals is a clinical-stage bi...

    Filing Type:    PU
    GENFIT S.A.

    GENFIT S.A.

    GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...

    GENFIT is a late-stage biopharmaceutical compan...

    Filing Type:    PU
    Mirum Pharmaceuticals, Inc.

    Mirum Pharmaceuticals, Inc.

    Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...

    Mirum Pharmaceuticals Inc. is a clinical-stage ...

    Filing Type:    PU
    Evoke Pharma, Inc.

    Evoke Pharma, Inc.

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...

    Filing Type:    PU
    Redhill Biopharma Ltd.

    Redhill Biopharma Ltd.

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a special...

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv...

    Filing Type:    PU
    Novan, Inc.

    Novan, Inc.

    Novan, Inc. is a clinical development-stage biotechnology company focused on lever...

    Novan, Inc. is a clinical development-stage bio...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.